SSA
PRME icon

Schonfeld Strategic Advisors’s Prime Medicine PRME Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.5K Buy
+20,189
New +$67K ﹤0.01% 2338
2025
Q4 		– Sell
-593,039
Closed -$3.29M – 2485
2025
Q3 		$3.29M Sell
593,039
-225,479
-28% -$916K 0.02% 791
2025
Q2 		$2.02M Buy
+818,518
New +$1.26M 0.01% 977
2024
Q2 		– Sell
-330,500
Closed -$2.31M – 2485
2024
Q1 		$2.31M Buy
+330,500
New +$2.51M 0.02% 941

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Schonfeld Strategic Advisors's PRME Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Prime Medicine (PRME) in Q2 2026: 20,189 shares worth $74.5K. The stake represents ﹤0.01% of the portfolio and ranks #2338 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in PRME as recently as Q3 2025.

Schonfeld Strategic Advisors first reported a position in PRME in Q1 2024 and has held it in 4 quarters since. The position peaked at $3.29M in Q3 2025. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Schonfeld Strategic Advisors held 20,189 shares of Prime Medicine worth $74.5K as of Q2 2026.
  • Prime Medicine was a new Schonfeld Strategic Advisors position in Q2 2026.
  • Prime Medicine made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2338 holding.
  • Schonfeld Strategic Advisors first reported a position in Prime Medicine in Q1 2024 and has held it in 4 quarters since.
  • Schonfeld Strategic Advisors's Prime Medicine position peaked at $3.29M in Q3 2025.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.